Helius Medical Technologies (Nasdaq:HSDT) - Aandelenkoers, Nieuws & Analyse

HSDT Overzicht aandelen

HSDT fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 28.64% per jaar groeien

De winst is de afgelopen 5 jaar met 7.8% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 19.7% per jaar dalen.

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

Heeft minder dan 1 jaar cash runway

+ 3 meer risico's

Helius Medical Technologies, Inc. Concurrenten

Tivic Health Systems

NasdaqCM:TIVC

US$1.5m

Avinger

NasdaqCM:AVGR

US$2.4m

Escalon Medical

OTCPK:ESMC

US$1.1m

Venus Concept

NasdaqCM:VERO

US$2.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Helius Medical Technologies
Historische aandelenkoersen
Huidige aandelenkoers	US$0.43
52 Week Hoogtepunt	US$9.50
52 Week Laag	US$0.37
Bèta	1.61
11 maand verandering	-27.10%
3 maanden verandering	-41.07%
1 Jaar Verandering	-93.38%
33 jaar verandering	-99.88%
5 jaar verandering	-99.94%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Aug 23

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Aug 05

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Aug 18

Rendement voor aandeelhouders

	HSDT	US Medical Equipment	US Markt
7D	-21.4%	1.7%	0.3%
1Y	-93.4%	21.4%	31.1%

Rendement versus industrie: HSDT presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 21.4 % opleverde.

Rendement versus markt: HSDT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.1 % opleverde.

Prijsvolatiliteit

Is HSDT's price volatile compared to industry and market?
HSDT volatility
HSDT Average Weekly Movement	19.9%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van HSDT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 20% ) van HSDT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	22	Dane Andreeff	heliusmedical.com

Helius Medical Technologies, Inc, een neurotechnologisch bedrijf, richt zich op het ontwikkelen, in licentie geven en verwerven van niet-implanteerbare technologieën voor de behandeling van symptomen veroorzaakt door neurologische aandoeningen of trauma. Het product van het bedrijf is de draagbare neuromodulatiestimulator, een niet-chirurgisch medisch apparaat dat bedoeld is voor kortdurende behandeling van loopproblemen als gevolg van symptomen van multiple sclerose en evenwichtsproblemen als gevolg van licht tot matig traumatisch hersenletsel, en dat gebruikt kan worden in combinatie met therapeutische oefeningen onder toezicht. Helius Medical Technologies, Inc. werd opgericht in 2014 en het hoofdkantoor is gevestigd in Newtown, Pennsylvania.

Helius Medical Technologies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Helius Medical Technologies zich tot de beurswaarde?
HSDT fundamentele statistieken
Marktkapitalisatie	US$1.62m
Inkomsten(TTM)	-US$8.86m
Inkomsten(TTM)	US$502.00k

3.1x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is HSDT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HSDT resultatenrekening (TTM)
Inkomsten	US$502.00k
Kosten van inkomsten	US$518.00k
Brutowinst	-US$16.00k
Overige uitgaven	US$8.84m
Inkomsten	-US$8.86m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.48
Brutomarge	-3.19%
Nettowinstmarge	-1,764.74%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde HSDT op de lange termijn?

Bekijk historische prestaties en vergelijking

HSDT Overzicht aandelen

Beloningen

Risicoanalyse

Helius Medical Technologies, Inc. Concurrenten

NasdaqCM:TIVC

US$1.5m

NasdaqCM:AVGR

US$2.4m

OTCPK:ESMC

US$1.1m

NasdaqCM:VERO

US$2.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Recent updates

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall to US$333.0k

Helius Medical makes CEO, CFO appointments

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Full year 2020 earnings released: US$11.80 loss per share (vs US$12.99 loss in FY 2019)

Revenue and earnings beat expectations

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

Helius Medical Technologies announces reverse stock split

Revenue beats expectations, earnings disappoint